Table 3 Prevalence of chemotherapy-related and antihormone therapy-related side effects in breast cancer patients 1, 2.

Chemotherapy (epirubicin, cyclophosphamide, paclitaxel, carboplatin)
Common:
10–100 %	Hair loss
< 10 %   to > 90 %	Nausea/vomiting (depending on the emetogenicity and antiemetic therapy)
1–84 %	Neurotoxicity
16–75 %	Cognitive impairment (“chemo brain”)
20–70 %	Insomnia
30–60 %	lethargy, chronic fatigue
25–40 %	febrile neutropenia (without previous cytostatic therapy)
10–40 %	Inflammation of the mucous membranes (mucositis, stomatitis)
5–60 %	Diarrhea
20–30 %	Depressive episodes
Rare:
2–20 %	Anemia
0.8–4 %	Cardiotoxicity in the adjuvant setting
< 2 %	Acute hypersensitivity reaction
Antihormone therapy (letrozole, tamoxifen, exemestane, anastrozole, fulvestrant)
Common:
34–40 %	Hot flushes, sweating
30–24 %	Bone, joint and muscle pain
20–30 %	Depressive mood
> 10 %	Fatigue
6–12 %	Osteoporosis
1–10 %	Increased appetite and weight gain
1–10 %	Insomnia
1–10 %	Nausea
1–10 %	Hair loss, dry skin
1–10 %	Hypercholesterolemia
5–9 %	Vaginal bleeding
Rare:
2–4 %	Thrombosis
1–2 %	Cardiovascular events